Effects of selonsertib in patients with diabetic kidney disease
Journal of the American Society of Nephrology Sep 14, 2019
Chertow GM, et al. – In a cohort of adults with type 2 diabetes and treatment-refractory moderate-to-advanced diabetic kidney disease, researchers assessed the efficacy and safety of selonsertib. In this phase 2 trial, participants (n = 333) were randomized (1:1:1:1) to receive either selonsertib (oral daily doses of 2, 6, or 18 mg) or placebo. Change from baseline eGFR at 48 weeks was assessed as the primary outcome. According to findings, selonsertib demonstrated safe in this patient population, and no dose-dependent adverse effects were identified over 48 weeks. Although this trial did not meet its primary endpoint, the possible efficacy of selonsertib in slowing diabetic kidney disease progression was suggested in exploratory post hoc analyses performed in this study.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries